Advancing cancer biotherapy with proteomics

Journal of Immunotherapy

Volumn 28, Issue 3, 2005, Pages 183-192

  Stroncek, David F ^a   Burns, Christine ^b   Martin, Brian M ^c   Rossi, Leonardo ^d   Marincola, Francesco M ^a   Panelli, Monica C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Pierce Boston Technology Center   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

ELISA; Granulocyte colony stimulating factor; Immunotherapy; Interleukin 2; Mass spectrometry; Proteomics

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANALYTIC METHOD; ARTHRALGIA; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; BLOOD TOXICITY; BONE PAIN; CANCER IMMUNOTHERAPY; CANCER THERAPY; CAPILLARY LEAK SYNDROME; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; HEADACHE; HIGH THROUGHPUT SCREENING; HUMAN; HYPOTENSION; INFLAMMATION; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MASS SPECTROMETRY; MELANOMA; MYALGIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RASH; RECURRENT DISEASE; REVIEW; THROMBOCYTOPENIA; VASCULITIS;

EID: 17844403476     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000162781.78384.95     Document Type: Review

References (48)

1. Srinivas PR, Kramer BS, Srivastava S. Trends in biomarker research for cancer detection. Lancet Oncol. 2001;2:698-704.
2. Howard BA, Wang MZ, Campa MJ, et al. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics. 2003;3:1720-1724.
3. Rosenberg SA. Development of effective immunotherapy for the treatment of patients with cancer. J Am Coll Surg. 2004;198:685-696.
4. Lotze M, Wang E, Marincola F, et al. Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients. J Immunother. 2005;28:79-119.
5. Paneli MC, Marincola FM. Proteomics and protein microarrays. In Lotze MT, Angus WT, eds. Measuring Immunity: The Immunologic Surrogates Handbook, 1st ed. Academic Press, Elsevier Science.
6. Panelli MC, White R, Foster M, et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med. 2004;2:17.
7. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353:1207-1210.
8. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-577.
9. Rapkiewicz AV, Espina V, Petricoin EF 3rd, et al. Biomarkers of ovarian tumours. Eur J Cancer. 2004;40:2604-2612.
10. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64:5882-5890.
11. Ornstein DK, Pruthi RS. Prostate-specific antigen. Expert Opin Pharmacother. 2000;1:1399-1411.
12. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer, part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017-1024.
13. Petricoin EF, Ornstein DK, Liotta LA. Clinical proteomics: applications for prostate cancer biomarker discovery and detection. Urol Oncol. 2004;22:322-328.
14. Ornstein DK, Rayford W, Fusaro VA, et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol. 2004;172:1302-1305.
15. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
16. Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin Oncol. 2000;27:194-203.
17. Panelli MC, Wang E, Phan G, et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 2002;3:35.
18. McDermott DF, Atkins MB. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther. 2004;4:455-468.
19. Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001;19:3477-3482.
20. Marincola FM. Interleukin-2. Biol Ther Cancer Updates. 1994;4:1-16.
21. Rossi L, Martin B, Hortin G, et al. Inflammatory protein profile during systemic high-dose interleukin-2 administration. Proteomics. (in press).
22. Boratynska M. Soluble cell adhesion molecules in chronic renal graft rejection. Pol Arch Med Wewn. 1998;100:410-418.
23. Correale J, Bassani Molinas Mde L. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol. 2003;140:198-209.
24. Zaccagni H, Fried J, Cornell J, et al. Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage. Front Biosci. 2004;9:1654-1659.
25. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104:1336-1342.
26. Hajilooi M, Sanati A, Ahmadieh A, et al. Circulating ICAM-1, VCAM-1, E-selectin, P-selectin, and TNF-alphaRII in patients with coronary artery disease. Immunol Invest. 2003;32:245-257.
27. Holmlund A, Hulthe J, Millgard J, et al. Soluble intercellular adhesion molecule-1 is related to endothelial vasodilatory function in healthy individuals. Atherosclerosis. 2002;165:271-276.
28. Lieuw-a-Fa M, Schalkwijk C, van Hinsbergh VW. Distinct accumulation patterns of soluble forms of E-selectin, VCAM-1 and ICAM-1 upon infusion of TNFalpha in tumor patients. Thromb Haemost. 2003;89:1052-1057.
29. Mortarini R, Borri A, Tragni G, et al. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res. 2000;60:3559-3568.
30. Correale J, Bassani Molinas MdeL. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol. 2003;140:198-209.
31. Porter JF, Shen S, Denhardt DT. Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase. Br J Cancer. 2004;90:463-470.
32. Maury CP, Liljestrom M, Laiho K, et al. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum. 2003;48:3068-3076.
33. Locker GJ, Kofler J, Stoiser B, et al. Relation of pro- and antiinflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2. Eur Cytokine Netw. 2000;11:391-396.
34. Stroncek D, Basil C, Khuu H, et al. Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor. Exp Hematol. (in review).
35. Stroncek DF, Clay ME, Petzoldt ML, et al. Treatment of normal individuals with G-CSF: donor experiences and the effects on peripheral blood CD34+ cell counts and the collection of peripheral blood stem cells. Transfusion. 1996;36:601-610.
36. Sloand EM, Kim S, Maciejewski JP, et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood. 2000;95:2269-2274.
37. Levesque JP, Liu F, Simmons PJ, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood. 2004;104:65-72.
38. Tanaka T, Ebisuno Y, Kanemitsu N, et al. Molecular determinants controlling homeostatic recirculation and tissue-specific trafficking of lymphocytes. Int Arch Allergy Immunol. 2004;134:120-134.
39. Christopherson KW 2nd, Hood AF, Travers JB, et al. Endothelial induction of the T-cell chemokine CCL21 in T-cell autoimmune diseases. Blood. 2003;101:801-806.
40. Thomas J, Liu F, Link DC. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr Opin Hematol. 2002;9:183-189.
41. Levesque JP, Liu F, Simmons PJ, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood. 2004;104:65-72.
42. LaBarge MA, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell. 2002;111:589-601.
43. Ojima K, Uezumi A, Miyoshi H, et al. Mac-1(low) early myeloid cells in the bone marrow-derived SP fraction migrate into injured skeletal muscle and participate in muscle regeneration. Biochem Biophys Res Commun. 2004;321:1050-1061.
44. McLoughlin RM, Hurst SM, Nowell MA, et al. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol. 2004;172:5676-5683.
45. Hurst SM, Wilkinson TS, McLoughlin RM, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14:705-714.
46. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863-14868.
47. He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood. 2003;101:1572-1581.
48. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000;24:227-235.